Sanofi India Board Approves 70th AGM, Final Dividend, and New Independent Director Appointment
Sanofi India's Board approved the 70th AGM on April 29, 2026, and a final dividend of ₹48 per share for FY25. Mr. Siraj Azmat Chaudhry was appointed as an Additional Director and Independent Director for five years from April 1, 2026. Record date for dividend is April 22, 2026.
The dividend payout and the appointment of a new director are significant corporate actions that could influence investor sentiment and governance, but do not immediately impact the company's operational or financial performance.
The approval of a final dividend and the appointment of an experienced independent director are positive developments for the company.
Sanofi India Limited announced the outcome of its Board Meeting held on Wednesday, 25th March 2026. The Board approved the convening of the Seventieth Annual General Meeting (70th AGM) on Wednesday, 29th April 2026, at 3:30 p.m. IST, to be conducted through Video Conferencing / Other Audio-Visual Means (VC/ OAVM).
Further, the Board confirmed the recommendation of a Final Dividend of ₹48 per equity share of ₹10 each for the Financial Year ended 31st December 2025, subject to shareholder approval at the 70th AGM. To facilitate this, the Register of Members and Share Transfer Books will be closed from Thursday, 23rd April 2026, to Wednesday, 29th April 2026, inclusive. The Record Date for determining eligibility for the Final Dividend is Wednesday, 22nd April 2026.
Additionally, the Board approved the appointment of Mr. Siraj Azmat Chaudhry (DIN: 00161853) as an Additional Director and Independent Director for a term of five consecutive years, commencing from 1st April 2026 to 31st March 2031. This appointment is also subject to the approval of the Members at the upcoming 70th AGM. Mr. Chaudhry, with an MBA from IIFT and B.Com (Hons) from SRCC, brings over 35 years of experience in leadership roles within the Agriculture and Food sectors, including his tenure as Chairman of Cargill India. He is not related to any existing directors and is not disqualified from directorship. The Board meeting commenced at 11:00 am and concluded at 12:05 pm.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.